88 results about "Ribosomal protein E-L30" patented technology

The present invention relates generally to compositions and methods for enhancing recombinational cloning of nucleic acid molecules. In particular, the invention relates to compositions comprising one or more ribosomal proteins and one or more additional protein components required for recombinational cloning. More particularly, the invention relates to such compositions wherein the ribosomal proteins are one or more E. coli ribosomal proteins, still more particularly wherein the ribosomal proteins are selected from the group of E. coli ribosomal proteins consisting of S10, S14, S15, S16, S17, S18, S19, S20, S21, L20, L21, and L23 through L34, and most particularly S20, L27, and S15. The invention also relates to the use of these compositions in methods for recombinational cloning of nucleic acids, in vitro and in vivo, to provide chimeric DNA molecules that have particular characteristics and/or DNA segments. The invention also relates to isolated nucleic acid molecules produced by the methods of the invention, to vectors comprising such nucleic acid molecules, and to host cells comprising such nucleic acid molecules and vectors.

The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes or proteins that bind mRNA in a cell type specific manner, and, thereby, the mRNA bound to the ribosomes or proteins that bind mRNA. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, cells are engineered to express a molecularly tagged ribosomal protein or protein that binds mRNA by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or protein that binds mRNA fused to a nucleotide sequence encoding a peptide tag. The tagged ribosome or mRNA binding protein can then be isolated, along with the mRNA bound to the tagged ribosome or mRNA binding protein, and the mRNA isolated and further used for gene expression analysis. The methods of the invention facilitate the analysis and quantification of gene expression in the selected cell type present within a heterogeneous cell mixture, without the need to isolate the cells of that cell type as a preliminary step.

The invention discloses a magnetic particle chemiluminescence quantitative assay kit for anti-ribosomal P protein antibody IgG. The kit includes: anti-ribosomal P protein antibody IgG calibrator; Ribosomal P protein antigen and bovine serum albumin-labeled Tris buffer; alkaline phosphatase-labeled goat anti-human polyclonal antibody and bovine serum albumin in Tris buffer; streptavidin-labeled magnetic particles and bovine serum albumin Serum albumin in Tris buffer; wash solution. Based on the traditional membrane strip immunoassay and enzyme-linked immunosorbent assay, the detection method of the kit increases the sensitivity and linear range by 3-5 orders of magnitude, and realizes quantitative detection in a real sense, with rapid response, reliable results, and It can be used in conjunction with a fully automatic chemiluminescence immunoassay analyzer to realize fully automatic use, and has irreplaceable important value for clinical diagnosis.

In this invention, a method is described that allows for the efficient creation and identification of validated biological materials that greatly enhance the ability to perform polysome-mediated RNA profiling, such as constitutive, cell type-, tissue type-, or condition-enhanced RNA profiling. The method relies on the use of a tri-partite plant binary expression vector comprised of the following components: a) a DNA promoter element that drives expression of a sequence specific transcription activator protein such as a LexA:Gal4 fusion protein in a unique desired pattern, b) a DNA promoter element comprising a target site for the transcriptional activator protein, such as opLexA, fused to a nucleotide encoding an epitope tagged ribosomal component protein and c) a DNA promoter element comprising a target site for the transcriptional activator protein, such as opLexA, fused to a nucleotide encoding an in vivo reporter protein. By visualization of the co-regulated reporter, this method allows for in planta confirmation that the promoter element is driving expression, such as constitutive, cell type-, tissue type-, or condition-enhanced expression, of the tagged ribosomal protein in the desired cell or tissue types.

The invention provides a construction method and use of Streptomyces roseosporus gene engineering bacteria. The construction method comprises: cloning upstream and downstream accessory key genes dptE, dptF, dptG, dptH, dptI and dptJ of a nonribosomal peptide synthetases (NRPS) gene in a daptomycin gene cluster; and constructing recombinant plasmids by using an Escherichia coli-Streptomyces shuttle expression vector. The recombinant plasmids are transferred into Escherichia coli ET12567 to culture the ET12567 and the Streptomyces roseosporus together, the Streptomyces roseosporus is transformed by a combined transfer method, a transformant is screened by brulamycin resistance and polymerase chain reaction (PCR) is performed for further confirmation. The Streptomyces roseosporus gene engineering bacteria constructed by the invention can be directly used in the industrial production of daptomycin and can improve yield and reduce cost.

The invention discloses a primer set for quickly identifying truth of beauveria bassiana in Chinese herbal medicine stiff silkworm and a molecular identifying method. The sequence of the primer set is respectively shown as SEQ ID NO.1-2. According to the invention, on the basis of the completion of high-throughput sequencing of complete genome of Guangdong beauveria bassiana mitochondria and bioinformatic comparative analysis of mitochondria complete genome of multiple cordyceps species, the difference of the beauveria bassiana mitochondria gene sequences at the aspect of geographical species is compared and obvious variation of ribosomal protein gene of beauveria bassiana is founded; a pair of primers for specifically detecting beauveria bassiana are screened on the basis of the design; the molecular identifying method for quickly and efficiently identifying truth of beauveria bassiana in Chinese herbal medicine stiff silkworm is established; the method is simple, convenient and quick, has high specificity, high sensitivity and wide application scope and can realize the identification for the truth of the beauveria bassiana from different producing places; a technical support is supplied for quality standardization and normalization and clinic drug safety of the Chinese herbal medicine stiff silkworm.

The present invention provides recombinant DNA comprising a transcription promoter and a downstream sequence to be expressed, in operable linkage therewith, wherein the transcription promoter comprises a region found upstream of the open reading frame of a highly expressed Phaffia gene, preferably a glycolytic pathway gene, more preferably the gene coding for Glyceraldehyde-3-Phosphate Dehydrogenase. Further preferred recombinant DNAs according to the invention contain promoters of ribosomal protein encoding genes, more preferably wherein the transcription promoter comprises a region found upstream of the open reading frame encoding a protein as represented by one of the disclosed amino acid sequences. According to a further aspect of the invention an isolated DNA sequence coding for an enzyme involved in the carotenoid biosynthetic pathway of Phaffia rhodozyma is provided.

The invention discloses a molecular marker associated with colorectal carcinoma metastasis and prognosis as well as application of the molecular marker. The molecular marker is a ribosomal protein analog RPL22L1 (Ribosomal protein L22-like 1). A research proves that the ribosomal protein analog RPL22L1 is associated with occurrence and development of tumors, expression levels of the ribosomal protein analog in clinical colorectal carcinoma tissues rise, the expression levels of the ribosomal protein analog are obviously associated with metastasis occurrence and poor prognosis, and the colorectal carcinoma metastasis can be promoted by multiple regulation pathways. According to the molecular marker associated with colorectal carcinoma metastasis and prognosis disclosed by the invention, by detecting the expression levels of RPL22L1 genes in the colorectal carcinoma, the RPL22L1 as a tumor molecular diagnosis marker is applied to clinical diagnosis of the colorectal carcinoma metastasis and prognosis evaluation, so that a new molecular marker is provided for early diagnosis on the colorectal carcinoma metastasis and prognosis evaluation of colorectal carcinoma patients.

This invention relates to a balsam pear seed ribosome inactivating protein(RIP) and its encode gene and application. This protein has one of the undermentioned amino acid residue sequence: (1) SEQ ID NO:1 in the sequence table; (2) carry out substitution, deficiency or addition of protein that possess activity of inhibiting ribosomal protein synthesis to one to ten amino acid residue of SEQ ID NO: 1 amino acid residue sequence in sequence table. This protein possess hereinafter point: (1) notable effect of resisting tumour and virus infection; (2) high security; (3) simple protein expression condition, easy purification. low cost.

The invention discloses three carboxyl substituted aromatic compounds (shown as Formulas (1-3)), which can antagonize ribosome proteins S1 (RpsA) of a ribosome 30S small subunit, effectively inhibit the growth of mycobacterium tuberculosis and pyrazinamide-resistance mycobacterium tuberculosis and can be used for preparing drugs for treating pyrazinamide-resistance tuberculosis and tuberculosis (as shown in Description).

The application discloses markers associated with organ transplant rejection and associated conditions, and in particular provides materials and methods for the diagnosis, prognosis or treatment of chronic rejection of transplanted organ such as heart and kidney. Examples of the markers include ribosomal protein L7, β-transducin, 1-TRAF (also known as TANK) or lysyl-tRNA synthetase, or antibodies against these antigens.

Disclosed are specific mutants of L3 and transgenic plants that produce them. The plants exhibit increased resistance to fungal toxins that target ribosomal L3 protein. Also disclosed are transgenic plants that co-produce L3 mutant and an RIP protein, and exhibit increased resistance to various fungal toxins and viruses, while reducing toxicity normally associated with production of the RIP. Uses of the L3 mutants in animals are further disclosed.

The invention relates to a detection method for testing a protein HOP and a heterogeneous ribosome protein C1/C2 which are both expressed in human liver tissue, as well as reagent box used in the method. The method is characterized in that: by means of the fluorescence differential two-dimensional electrophoresis method -MALDI-TOF/TOF, the inventor manages to identify the overexpression of the two proteins on human liver cell carcinoma tumor tissue, and carries out immune histochemistry validations of Western bolt and large amount of samples over the expression levels in the human liver cell carcinoma tissue. The detection method for proteins and the reagent box can be used in the detections for clinical or research purposes.

The invention discloses a giant panda ribosomal subunit gene RPL23a recombinant protein and application thereof in preparing anti-cancer drugs. The amino acid sequence of the recombinant protein is defined by SEQ ID NO: 7. The inhibitory effect of giant panda ribosomal subunit gene RPL23a recombinant protein on growth of Hep-2 cells is observed by acting the giant panda ribosomal subunit gene RPL23a recombinant protein on the Hep-2 cells, which reveals the anticancer function of the giant panda ribosomal subunit gene RPL23a recombinant protein and provides scientific basis and resources for developing anti-cancer protein drugs and studying on anti-cancer mechanism.

The invention discloses specific nucleotide of human ribosomal protein molecules hRrp15p. The nucleotide comprises a) a nucleotide sequence shown as SEQ ID NO: 1 or a complementary DNA sequence thereof, and b) a nucleotide sequence formed by deletion, substitution or insertion of one or more bases in the a) and still having nucleotide function, wherein the full length of the nucleotide shown as SEQ ID NO: 1 is 849 bases. The amino acid sequence such as SEQ ID NO: 2 corresponding to the nucleotide sequence has 282 amino acids. Polyclonal antibodies of hRrp15p are prepared, and multiple mutants of the protein molecules are constructed; and intracellular expression of the hRrp15p, sub-cellular positioning and influence of the protein molecules on nucleolin nucleolus positioning are deeply researched. Therefore, the problem hollow to position the nucleolin in a nucleolus structure is solved, the formation of the nucleolus structure is promoted, and morphological basis is laid for exertion of functions of the nucleoli in cells.

The invention provides a gene of strain ribosome protein L7/L12 of brucellosis M5 of sheep type and encoded protein and application thereof. The encoded protein of the gene of the invention has an amino acid sequence shown in SEQ ID No.2. The gene of the invention can be used for preparing gene vaccine. For example, the siRNA or shRNA or microRNA can be synthesized and used for gene silencing by the sequence of the invention. By preparing the expression protein of the gene of the invention, the recombinant protein vaccine can be researched, or a test kit can be developed, which provides an effective solving way for the brucellosis.

The invention belongs to the field of biotechnology, and specifically relates to expression purification, a crystal structure and an application of a mycobacterium tuberculosis ribosomal protein S7. The protein S7 contains 156 amino acids, has the molecular weight of about 17.6 kDa, and has the isoelectric point of about 10.56; the protein S7 has high soluble expression in an expression strain escherichia coli rosetta (DE3), and has good purity and homogeneity. A three-dimensional structure of the ribosomal protein S7 is obtained by an X-ray diffraction method; the resolution ratio reaches up to 1.80 Angstroms; the space group is P2[1]2[1]2[1]. The structure is integrally composed of 6 alpha spirals and 2 beta spirals, wherein an alpha spiral beam structure composed of alpha spiral 1, alpha spiral 2, alpha spiral 3, alpha spiral 4 and alpha spiral 5 has interaction with other proteins on other ribosomes; a beta hairpin structure connected between alpha 3 and alpha 4 has an RNA recognition function. The three-dimensional structure of the ribosomal protein S7 has broad application prospects in screening of novel anti-tuberculosis drugs.